NCT03926988招募中不适用
A Prospective, Open-Label, Multi-Center, Registry Designed to Assess the Safety, Performance and Efficacy of the NeVa Stent Retriever in the Treatment of Large Vessel Occlusion Strokes
Vesalio1 个研究点 分布在 1 个国家目标入组 400 人开始时间: 2019年4月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 400
- 试验地点
- 1
- 主要终点
- Recanalization rate of occluded target vessel
研究概览
简要总结
A prospective, open label, 90-day study designed to assess the safety, performance and efficacy of thrombus removal in subjects presenting with acute ischemic stroke with the NeVa stent retrievers.
详细描述
This is a prospective, open label, multi-center registry designed to assess the safety, performance and efficacy of the NeVa stent retriever in the treatment of large vessel occlusion strokes. Up to 400 subjects at up 20 sites will participate in the study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Only subjects already treated with the NeVa devices can be considered for enrollment.
- •Clinical signs and symptoms consistent with the diagnosis of an acute ischemic stroke, and subject belongs to one of the following subgroups:
- •Subject has failed IV t-PA therapy
- •Subject is contraindicated for IV t-PA administration
- •NIHSS score ≥ 6
- •Pre-stroke mRS score of ≤ 1
- •Intracranial arterial occlusion of the distal intracranial carotid artery or middle cerebral artery (M1/M2), anterior cerebral artery (ACA), posterior cerebral artery (PCA), basilar artery, or vertebral artery demonstrated with DSA.
- •Thrombectomy procedure can be initiated within 24 hours from symptom onset (defined as time last known well [TLKW])
- •Imaging Inclusion Criteria:
- •Non-Contrast CT Selection (if CT Perfusion or MRI not utilized): ASPECTS 6-10 if treatment started 0-6 hours from TLKW ASPECTS 8-10 if treatment started 6-24 hours from TLKW
- •CT Perfusion core ≤50 cc
- •MRI DWI core ≤50 cc
- •Subject or legal representative is able and willing to give informed consent within 48 hours after the intervention.
排除标准
- •Pre-existing medical neurological or psychiatric disease that would confound the neurological or functional evaluations, e.g. dementia with prescribed anti-cholinesterase inhibitor (e.g. Aricept).
- •Cardiopulmonary resuscitation, significant cardiac arrhythmia, evidence of ongoing myocardial infarction, concern for pre- treatment pulmonary aspiration.
- •Clinical symptoms suggestive of bilateral stroke or stroke in multiple territories
- •Cerebral vasculitis
- •History of severe allergy to contrast medium.
- •Known allergy to NeVa materials (nitinol, stainless steel)
- •Suspicion of aortic dissection, septic embolus, or bacterial endocarditis
- •Systemic infection
- •Significant mass effect with midline shift
- •Evidence of intracranial tumor (except small meningioma)
- •Inability to deploy NeVA device for at least one pass for any other reason
- •Life expectancy less than 6 months
- •Any other condition that, in the opinion of the investigator, precludes an endovascular procedure or poses a significant hazard to the subject if an endovascular procedure was performed.
结局指标
主要结局
Recanalization rate of occluded target vessel
时间窗: post-procedure day 0
Recanalization rate of occluded target vessel (defined by an eTICI score ≥ 2b) following three or less passes using the NeVa device(s).
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
不适用
The Vesalio NeVa Stent Retriever Study for Treatment of Large Vessel Occlusion StrokesAcute Ischemic StrokeNCT03927001Vesalio150
进行中（未招募）
不适用
The Vesalio NeVa Stent Retriever Study for Treatment of Large Vessel Occlusion Strokes: CLEAR StudyAcute Ischemic StrokeNCT04514562Vesalio120
已完成
不适用
StimRouter Registry Clinical ProtocolChronic PainNervous System DiseasesPeripheral Nervous System DiseasesPeripheral Nervous System ProblemPeripheral Nerve InjuriesPeripheral NervousPeripheral NeuropathyNCT03913689Bioness Inc62
招募中
2 期
The Safety and Efficacy of Rapamycin on Communicating Hydrocephalus Secondary to Intraventricular HemorrhageCommunicating HydrocephalusCerebral Intraventricular HemorrhageSecondary Normal Pressure HydrocephalusPost Hemorrhagic HydrocephalusNCT06563817Beijing Tiantan Hospital53
已完成
4 期
A study to evaluate the efficacy and safety of vestige spirulina capsules for the immunity in healthy patients.CTRI/2022/09/045585Vestige Marketing Pvt Ltd50